BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Immunotope, Inc. Receives Second Investment from Ben Franklin Technology Partners of Southeastern PA


6/26/2007 11:14:13 AM

DOYLESTOWN, Pa., June 26 /PRNewswire/ -- Immunotope Inc. announced today that Ben Franklin Technology Partners of Southeastern PA (BFTP/SEP) has made a second $350,000 investment to continue funding the company's Phase I IMT- 1012 immunotherapeutic vaccine clinical trial. BFTP/SEP made a first $350,000 investment in August 2006, enabling the company to manufacture the vaccine and obtain necessary regulatory approvals. The second investment will fund patient treatment and evaluation studies.

Immunotope's IMT-1012 multivalent cancer therapeutic vaccine is the first cancer vaccine to combine 12 different novel antigens that each target a different, critical pathway present in highly aggressive ovarian and breast tumors. IMT-1012 is designed to destroy tumor cells and prevent recurrence and metastasis through activation of long-lasting, systemic cellular immunity. The vaccine is being developed to treat advanced-stage ovarian and breast cancer patients who typically experience cancer recurrence within 10 months after surgery, and for whom there are no further treatment options.

Ramila Philip, Ph.D., Immunotope President and Chief Scientific Officer, stated, "This clinical study is a significant step forward for our therapeutic vaccine platform. We are pleased by BFTP/SEP's timely support for a treatment that we believe may have significant advantages over existing standards of care and other therapies now being tested in the clinic. Because this novel antigen mixture targets multiple critical tumor pathways, we believe that it has the potential to redefine the future of immunotherapeutic vaccine design for many forms of cancer."

About Immunotope, Inc.

Immunotope is a clinical stage biotechnology company developing immunotherapy products for the treatment of cancer and chronic viral infections. Immunotope focuses on the critical, unmet need to diagnose cancer at its earliest stages and to provide effective treatments that destroy tumors and prevent recurrence and metastasis. The company's lead product, the IMT- 1012 multivalent therapeutic vaccine, is now being evaluated in a Phase I clinical trial at the Duke University Comprehensive Cancer Center in advanced- stage ovarian and breast cancer patients. Immunotope's viral immunotherapy program is centered on vaccines for the treatment and prevention of chronic hepatitis, Dengue Virus, influenza and HIV. Immunotope is also developing autoantibody-based tests for early diagnosis of ovarian and prostate cancer. www.immunotope.com

Since 1982, Ben Franklin Technology Partners of Southeastern Pennsylvania has served as a catalyst for stimulating entrepreneurial potential by developing systems to accelerate the transition of scientific discovery and technology development to commercialization. Part of a statewide network in Pennsylvania, BFTP/SEP provides entrepreneurs and established businesses the capital, knowledge and networks they need to compete in the global marketplace. BFTP/SEP has provided more than $130 million to over 1,600 regional enterprises. BFTP/SEP is a founding partner of the Nanotechnology Institute (NTI) and the Mid-Atlantic Nanotechnology Alliance (MANA(R)), and is funded by Pennsylvania's Department of Community and Economic Development. For additional information, visit www.sep.benfranklin.org

Contacts: Immunotope, Inc.: Lorraine Keller, Ph.D., Executive Vice President 215-589-6352 or lkeller@immunotope.com Richard Lewis Communications, Inc., Gregory Tiberend 212-827-0020 or gtiberend@rlcinc.com

Immunotope Inc.

CONTACT: Lorraine Keller, Ph.D., Executive Vice President, ImmunotopeInc., +1-215-589-6352, or lkeller@immunotope.com, or Gregory Tiberend ofRichard Lewis Communications, Inc., +1-212-827-0020, orgtiberend@rlcinc.com, for Immunotope Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES